Cover Image
市場調查報告書

Poly (ADP核糖) 聚合酵素1 (ADP核糖基轉移酶白喉毒素樣1,PARP-1,NAD (+) ADP-核糖基轉移酶1,ADPRT 1,Poly (ADP核糖) 合成酶1,EC 2.4.2.30):開發中產品分析

Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363570
出版日期 內容資訊 英文 116 Pages
訂單完成後即時交付
價格
Back to Top
Poly (ADP核糖) 聚合酵素1 (ADP核糖基轉移酶白喉毒素樣1,PARP-1,NAD (+) ADP-核糖基轉移酶1,ADPRT 1,Poly (ADP核糖) 合成酶1,EC 2.4.2.30):開發中產品分析 Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016
出版日期: 2016年06月22日 內容資訊: 英文 116 Pages
簡介

本報告提供全球各國的Poly (ADP核糖) 聚合酵素1 (別名ADP核糖基轉移酶白喉毒素樣1、PARP-1、NAD (+) ADP-核糖基轉移酶1、ADPRT 1、Poly (ADP核糖) 合成酶1或EC 2.4.2.30) 相關的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊 ,為您概述為以下內容。

目錄

  • 簡介
    • 分析範圍
  • Poly (ADP核糖) 聚合酵素1 (ADP核糖基轉移酶白喉毒素樣1、PARP-1、NAD (+) ADP-核糖基轉移酶1、ADPRT 1、Poly (ADP核糖) 合成酶1、EC 2.4.2.30)的概要
  • 治療藥的開發情形
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的治療藥
  • 各大學、研究機關開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • AbbVie Inc.
    • American Gene Technologies International Inc.
    • AstraZeneca Plc
    • BeiGene, Ltd.
    • Clovis Oncology, Inc.
    • Eisai
    • Hager Biosciences, LLC
    • IMPACT Therapeutics, Inc.
    • Jeil Pharmaceutical Co., Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.
    • 田邊三菱製藥
    • Nerviano Medical Sciences S.r.l.
    • 武田藥品工業
    • Tesaro, Inc.
    • Teva Pharmaceutical Industries Ltd.
  • 藥物簡介
    • ABT-767
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的發展情形
    • AGPD
    • AZ-0108
    • BGB-290
    • CK-102
    • E-7449
    • fluzoparib
    • IMP-04297
    • JPI-289
    • MP-124
    • niraparibu
    • NMSP-118
    • NMSP-648
    • NMSP-914
    • oraparibu
    • R-503
    • 磷酸rukaparibu (rucaparib phosphate)
    • 有機磷酸中毒的PARP-1抑制用/AChE活性化用小分子
    • 未公開的症狀的PARP-1抑制用小分子
    • 結腸癌症的PARP-1抑制用小分子
    • 腫瘤的PARP-1/-2/-3及一氧化氮 (NO) 標的小分子
    • veliparib
    • XZ-120312
    • YHP-743
  • 開發暫停的產品
  • 開發中止的產品
  • 值得注意的最新趨勢、新聞稿 (共15件)
  • 附錄

圖表一覽

目錄
Product Code: GMDHC0105TDB

Summary

Global Markets Direct's, 'Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016', provides in depth analysis on Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted pipeline therapeutics.

The report provides comprehensive information on the Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30)
  • The report reviews Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD (+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Overview
  • Therapeutics Development
    • Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Products under Development by Stage of Development
    • Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Products under Development by Therapy Area
    • Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Products under Development by Indication
  • Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Products under Development by Companies
  • Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Products under Development by Universities/Institutes
  • Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • American Gene Technologies International Inc.
    • AstraZeneca Plc
    • BeiGene, Ltd.
    • Clovis Oncology, Inc.
    • Eisai Co., Ltd.
    • Hager Biosciences, LLC
    • IMPACT Therapeutics, Inc.
    • Jeil Pharmaceutical Co., Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Mitsubishi Tanabe Pharma Corporation
    • Nerviano Medical Sciences S.r.l.
    • Takeda Pharmaceutical Company Limited
    • Tesaro, Inc.
    • Teva Pharmaceutical Industries Ltd.
  • Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Drug Profiles
    • ABT-767 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AGPD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZ-0108 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGB-290 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CK-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-7449 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fluzoparib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMP-04297 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JPI-289 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MP-124 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • niraparib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NMSP-118 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NMSP-648 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NMSP-914 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • olaparib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-503 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rucaparib phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit PARP-1 for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PARP-1 for Colon Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target PARP1, 2, 3 and NO for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • veliparib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XZ-120312 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YHP-743 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Dormant Projects
  • Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Discontinued Products
  • Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Featured News & Press Releases
    • Jun 06, 2016: Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting
    • Jun 05, 2016: LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer
    • Jun 04, 2016: TESARO Provides Update on niraparib at ASCO Investor Briefing
    • Jun 04, 2016: Rucaparib shows clinical benefit in pancreatic cancer patients with BRCA mutation
    • May 19, 2016: Clovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting
    • May 18, 2016: TESARO Announces Three Abstracts on Niraparib to be Presented at the 2016 American Society of Clinical Oncology Annual Meeting
    • May 18, 2016: AstraZeneca provides top-line results from Lynparza GOLD trial in advanced gastric cancer
    • May 18, 2016: AbbVie To Present Data on Veliparib at at ASCO 2016
    • Apr 27, 2016: Lynparzatm (Olaparib) Now Available To NHS Patients In England And Wales With BRCA-Mutated Ovarian Cancer
    • Apr 18, 2016: AstraZeneca Presents New Data On PARP Inhibitor Lynparza (olaparib) at the AACR 2016 Annual Meeting
    • Apr 14, 2016: Myriad Genetics announces presentation on niraparib study at the 2016 American Association for Cancer Research Annual Meeting
    • Jan 28, 2016: Lynparza (olaparib) granted Breakthrough Therapy designation by US FDA for treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer
    • Jan 27, 2016: NICE recommends olaparib for ovarian cancer
    • Jan 25, 2016: Clovis Oncology Names Dale Hooks as Chief Commercial Officer, Provides Update On Rucaparib
    • Dec 11, 2015: NICE intends to recommend olaparib for ovarian, fallopian tube and peritoneal cancer after company provides more information
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by AbbVie Inc., H1 2016
  • Pipeline by American Gene Technologies International Inc., H1 2016
  • Pipeline by AstraZeneca Plc, H1 2016
  • Pipeline by BeiGene, Ltd., H1 2016
  • Pipeline by Clovis Oncology, Inc., H1 2016
  • Pipeline by Eisai Co., Ltd., H1 2016
  • Pipeline by Hager Biosciences, LLC, H1 2016
  • Pipeline by IMPACT Therapeutics, Inc., H1 2016
  • Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016
  • Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016
  • Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Pipeline by Nerviano Medical Sciences S.r.l., H1 2016
  • Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Pipeline by Tesaro, Inc., H1 2016
  • Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016
  • Dormant Projects (Contd..3), H1 2016
  • Dormant Projects (Contd..4), H1 2016
  • Dormant Projects (Contd..5), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top